In CKD patient on phosphate control, there is still high PTH; which pharmacologic option might be considered?

• A. Dialysis Schedule Adjustment
• B. Phosphate Binders With Vitamin D Analogues
• C. Dietary Restriction Reduction
• D. Osmotic Diuretics

Answer: (B)

When CKD leads to secondary hyperparathyroidism, the driving factors are phosphate retention and reduced active vitamin D, both of which push PTH up. If PTH remains high despite phosphate control, a pharmacologic approach that targets both issues is to use phosphate binders to lower serum phosphate and add a vitamin D analogue to suppress PTH production and help restore calcium balance. This combination directly reduces the stimulus for PTH and dampens parathyroid activity, which is why it’s the best choice in this setting. Dialysis schedule adjustments and dietary restrictions may help with phosphate management or overall fluid balance but are not pharmacologic treatments aimed at lowering PTH. Osmotic diuretics aren’t used to treat this condition.